Fifth issued patent in the U.S. for QTORIN™ rapamycin with anticipated patent life extending into 2038QTORIN™ rapamycin has the potential to be ...

Researchers from the International Institute of Molecular and Cell Biology in Warsaw (IIMCB) have described a new mechanism ...

We are thrilled to welcome Chris to our team at this exciting time for Design, as we advance our portfolio of GeneTAC ® small molecules toward key clinical milestones,” said Pratik Shah, Ph.D., ...

Natural gas back at mid-$3 on modest storage build, impending data blackout By Investing.com - Oct 26, 2023 9 Investing.com - US natural gas futures jumped 3% on Thursday, returning to the mid-$3 ...

Learn about Brink Therapeutics as it raises $4 million to go beyond CRISPR with engineered recombinases in CAR T therapy.

Two dose levels of a single-administration gene therapy were well-tolerated and led to functional improvements in ambulatory ...

Nektar Therapeutics’s NKTR share price has surged by 6.81%, which has investors questioning if this is right time to sell.

As the world reels from the aftermath of the Myanmar earthquake, seismologists have warned there is a heightened danger of further disasters.

Its product portfolio and rights are licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, natural killer cell therapy technology.

And who can forget Chernobyl? Not exactly a natural disaster, but the eerily quiet, radiation-drenched aftermath had all the hallmarks of one. Let’s count down our top 10 picks for the best shows on ...

Potential Prelude Therapeutics Incorporated (NASDAQ:PRLD) shareholders may wish to note that the Founder, Krishna Vaddi, recently bought US$467k worth of stock, paying US$0.69 for each share.

NEW YORK – Marengo Therapeutics is expediting development of a novel class of T-cell engagers that promote expansion of specific sets of immune cells, betting that they will trigger a response that ...